


Azido-PEG4-alcohol

Cat. No.:	HY-22340		
CAS No.:	86770-67-4		
Molecular Formula:	C ₈ H ₁₇ N ₃ O ₄		
Molecular Weight:	219.24		
Target:	PROTAC Linkers		
Pathway:	PROTAC		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

H₂O : ≥ 100 mg/mL (456.12 mM)
 DMSO : 33.33 mg/mL (152.03 mM; ultrasonic and warming and heat to 80°C)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	4.5612 mL	22.8061 mL	45.6121 mL
	5 mM	0.9122 mL	4.5612 mL	9.1224 mL
	10 mM	0.4561 mL	2.2806 mL	4.5612 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 100 mg/mL (456.12 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Azido-PEG4-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs^[1]. Azido-PEG4-alcohol is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with

	molecules containing DBCO or BCN groups.
IC₅₀ & Target	PEGs
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Zhang F, et al. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. *Bioorg Med Chem.* 2020 Jan 1;28(1):115228.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA